In this insightful discussion, Amy Kruse, a neuroscientist and Chief Investment Officer at Satori Neuro, and Matias Serebrinsky, co-founder of PsyMed Ventures, delve into the transformative role of AI and biotechnology in mental health. They explore the hype around psychedelics and emphasize the significance of the gut-brain axis. The duo also highlights the evolution of neurotechnology and the potential for innovative treatments, alongside the challenges of funding health tech startups, particularly focusing on mental wellness and women's health.
